MedTrace Logo

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

NCT00547144 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2012-11-08

No results posted yet for this study

Summary

To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer

Conditions

Interventions

DRUG

Gemcitabine

1000 mg/m2 intravenoulsy once a week according to protocol schedule

PROCEDURE

Dendritic Cell Immunotherapy

The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)

Sponsors & Collaborators

  • George Albert Fisher

    lead OTHER

Principal Investigators

  • Edgar G Engleman · Stanford University

  • George Albert Fisher M.D. Ph.D. · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547144 on ClinicalTrials.gov